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Nevirapine (NVP) uptake  




NVP coverage was defined as the proportion of HIV-infected mothers and HIV-exposed infant 
pairs that received both the maternal and infant SD-NVP doses where the maternal NVP was 
indicated by high performance liquid chromatography (HPLC) of cord blood collected at 















The objective was to assess the uptake and coverage of SD-NVP to prevent mother-to-child 
transmission of HIV in women of unknown HIV status presenting in labour a sample of delivery 
sites in the Western Cape. This monitoring activity also accurately measures the prevalence of 
HIV among pregnant women and ascertains the proportion of HIV exposed infants delivered to 
these mothers, who received NVP prophylaxis to prevent MTCT. 
 
Design 
Anonymous, unlinked specimens of cord blood from discarded placentas were tested for HIV 
antibodies to determine population-level information on HIV infection and NVP coverage 
among all women delivering in the facilities. Uptake was measured by counting the number of 
women who were recorded to have accepted NVP when offered while coverage was measured 
by using the cord blood NVP assay. 
 
Results 
A total of 2198 (96.5%) cord blood specimens were collected from women at delivery. From 
these, 1876 (85.4%) women received pre-test counselling. Of those who were counselled, 1851 
(84.2%) were tested for HIV and 365 (19.3%) tested positive.  Amongst those who were 
infected, 229 (62.7%) received SD-NVP and but only 57.8% adhered to SD-NVP according to 












having received SD-NVP. There was no significant difference in SD-NVP uptake between the 
two facilities. The overall NVP coverage (mother and infant doses) was 55.3%. 
 
 Conclusions 
The NVP coverage of 55.3% is poor. In order for PMTCT services to be successful, each 
mother-infant pair should go through a rigorous cascade of events that include HIV testing, 
receipt of results, diagnosis and drug adherence. The attrition cascade in this study was described 
using a new cord blood surveillance methodology. Coverage fails for a number of reasons and 
interventions are likely to differ from one facility to another. Appropriate interventions should be 
































AIDS is an acronym for Acquired Immune Deficiency Syndrome and is the end stage disease 
manifestation of an infection with the human immunodeficiency virus (HIV) as a result of the 
body’s immune system being compromised. HIV is a retrovirus that infects cells of the immune 
system, destroying or impairing their function. As the infection progresses, the immune system 
therefore becomes weaker and the person becomes more susceptible to additional infections.  
 
Although HIV has been isolated from most body fluids such as blood, cerebrospinal fluid, saliva, 
semen, vaginal secretions and breast milk, it is usually transmitted through blood, vaginal fluid 
and semen. Most individuals are infected with HIV through sexual contact, in utero, during 
delivery, during breastfeeding and through blood and blood products, via transfusions or needles 
contaminated with HIV-infected blood. 
 
 
1.1 The virus-HIV 
HIV belongs to an unusual class of viruses called retroviruses. The family of retroviruses 












facilitates the production of a DNA copy from an RNA genome. There are two strains of HIV: 
HIV-1, which is responsible for the worldwide pandemic and HIV-2. The geographic distribution 
of HIV-2 virus is confined to West African countries as well as the former Portuguese colonies 
of Angola and Mozambique (Schoub, 1994). Both strains affect the immune system in a similar 
way and both have similar mechanisms of transmission. HIV-2 nonetheless, appears to be less 
virulent than HIV-1 and is not transmitted as easily as HIV-1 especially from mother to child 
(Hubbley J, 2002).  
 
1.2 History of AIDS 
The HIV/AIDS epidemic became apparent in 1981 when doctors in three different hospitals in 
Los Angeles noticed previously rare diseases in five young men under their care. All five were 
diagnosed with pnuemonocystis carnii pneumonia (IP). They were also found to have been 
infected with cytomegalovirus (CMV), a virus common in immunosuppressed patients. The five 
men were all sexually active homosexuals. It was only in 1983 that the syndrome AIDS was first 
defined and HIV was identified as the cause of AIDS and the first HIV antibody test became 
available (Schoub, 1994).   
 
In 1983, there was evidence of a heterosexual epidemic emerging on the African continent. The 
epidemic has since increased dramatically in the sub-Saharan region of Africa and particularly, 
southern Africa. In 1987 the first therapy for AIDS called Zidovudine was approved for use in 
the USA. The first treatment regimen to reduce mother to child transmission was developed in 


















1.3 Epidemiology of HIV/AIDS 
 
HIV/AIDS, however, still remains the most prevalent epidemic worldwide despite efforts to 
improve access to antiretroviral treatment in most countries. In 2005 about 3.1 million people 
died of HIV/AIDS. More than half a million of that number were children. At the end of 2006, 
2.3 million children under the age of 15 were estimated to be living with HIV with 15 million 
already orphaned due to HIV/AIDS. Of the 2.3 million new infections, 530 000 were children, 
with 90% being infected through mother-to-child transmission (Richard et al., 2007). 
 
In 2008, there were 2.7 million (95% CI: 2.4 million-3.0 million) incident cases of HIV 
worldwide. Young people between 15-24 years accounted for half of all new infections. In sub-
Saharan Africa, the incident cases were estimated at 1.9 million (95% CI: 1.6 million–2.2 
million) people. The estimated number of people living with HIV worldwide in 2008 was 33.4 
million (95% CI: 31.1 million-35.8 million). The prevalence of people living with HIV has 
increased as a result of the ongoing number of new infections each year and the benefit of more 
widely available antiretroviral therapy (UNAIDS/WHO, 2009). The estimated number of deaths 
due to AIDS in 2008 was 2.0 million (95% CI: 1.7-2.4million) worldwide, of which 76% 
occurred in sub-Saharan Africa (UNAIDS update, 2009).  
 
Sub-Saharan Africa still remains the area most affected by the epidemic with approximately 22.4 












population. In 2008, an estimated 1.9 million people in sub-Saharan Africa were newly infected 
with HIV with 61% being women.  
 
Mother to child transmission (MTCT) is the primary means by which children become infected 
with HIV (UNAIDS update, 2009, WHO, 2005, Sperling et al., 1994). The majority of infections 
occur at delivery and through breast feeding. 
 
1.4 HIV/AIDS in South Africa 
 
South Africa has the largest number of people infected with HIV in the world (UNAIDS/WHO, 
2008). Data collected from antenatal clinic surveillance at public sector services suggest that 
HIV infections might be levelling off (Figure 1). The prevalence among pregnant women was 
30.2% (95% CI: 29.1-31.2) in 2005, 29.1% (95% CI: 28.3%-29.9%) in 2006 and 29.4% (95% 
CI: 28.5–30.1) in 2007 and 29.3% (95% CI: 28.5%–30.1%) in 2008 (Department of Health 
South Africa, 2009). A decline in the prevalence might be due to increased mortality but not 
necessarily a drop in new infections, while an increase in prevalence may be due to, increased 
access to antiretrovirals. The epidemic varies greatly among the nine provinces of South Africa, 
with the prevalence amongst pregnant women being 16.1% (CI: 12.6%–20.2%) in the Western 
Cape and 38.7% (95% CI: 37.2%–40.1%) in the KwaZulu-Natal province (Department of Health 
South Africa, 2009). The overall prevalence in South Africa is similar to other southern African 


















Figure 1: HIV prevalence trends among women attending antenatal services in the public sector 























Figure 2: Median HIV prevalence in 7 southern African countries (including South Africa). 
 
 
In response to the AIDS pandemic in South Africa, the National Strategic Plan (NSP) for 
HIV/AIDS and STD was initiated by the late Dr. Manto Tshabalala Msimang in 1999. The NSP 
was implemented in 2000 for the period 2000-2005 and recently revised for the period 2007-
2011.The main aims of the NSP are; to reduce the number of new HIV infections by 50%, 
reduce the impact of HIV/AIDS on individuals, families, communities, and society by expanding 
access to appropriate treatment, care and support to 80% of all people diagnosed with HIV. 
Incidence reduction will be specifically targeted at people in the 15-24 year age group as this is 
the group with the highest incidence of HIV (Williams et al., 2003). 
 
In response to the HIV epidemic worldwide, the UN General Assembly in 2001, set a target of 












and the provision of PMTCT services to 80% of all those in need by 2010 (UN General 
Assembly, 2001, Tabitha et al., 2006). 
 
1.5 Epidemiology of Mother-to-child transmission of HIV  
1.5.1 Major risk factors for MTCT 
 
Recent sero-conversion or advanced maternal disease during pregnancy and in the breastfeeding 
period resulting in hhigh HIV-1 viral load and low CD4 cell count, breast abscess, cracked 
nipples and associated factors such as mastitis that increase breast milk HIV viral load, are known 
maternal related factors for HIV transmission from mother to child (Coovadia et al., 2007).  
 
Mofenson et al., 1999 showed that the mean CD4 cell count was lower among women who 
transmitted infection to their infants compared to those who did not transmit the infection. Other 
studies have shown that, advanced maternal immune suppression and high HIV viral load were 
also associated with increased risk of perinatal HIV transmission (Mayaux et al., 1995; Sperling 
et al., 1996; McGowan J & Shah  S, 2000).  
 
1.5.1.1 Breastfeeding and MTCT risk 
 
Breast feeding results in over 200,000 paediatric HIV infections annually and is one of the ways 
through which MTCT occurs. In South Africa alone, breast feeding accounts for one third to half 
of all MTCT cases (Weaver et al., 2000). According to a meta-analysis, the cumulative postnatal 
transmission was estimated to be 8.9 transmissions/100 child-years of breast-feeding (95% CI, 












probability of 9.3% (95% CI 7.8 – 10.2 transmissions/100 child - years of breast feeding) after 
eighteen months of breast feeding (Coutsoudis et al., 2004).. Transmission through breast feeding 
was reported to be even higher in places where malnutrition and infectious diseases are common 
(Semba et al, 1995, Landers et al., 1996). Table 1 shows the percentages of HIV 1 infection 
acquired by different routes.  
 





Intrauterine 20% 30% 




These rates are observed in the absence of interventions to reduce MTCT 
  Adapted from Bertoli J et al. J Infect Dis 1996; 174:722 
 
Mechanisms that may influence breast milk HIV-1 viral load and the relationship between breast 
milk HIV-1 viral load and MTCT of HIV are unknown (Kreiss J.,1997). Mastitis is an 
inflammatory process in the breast and has been implicated in the exacerbation of MTCT because 
of the presence of plasma derived components and inflammatory cells in breast milk during 
mastitis. HIV-1 infected lymphocytes could raise HIV-1 viral load in breast milk and add to the 
risk of HIV-1 transmission from mother to child (Morton JA, 1994; Semba et al., 1999). Recent 
HIV infection or re-infection is an important risk factor for transmission through breast milk as it 
doubles the risk when compared to a woman with established infection due to the high viral load 













In 1999, Semba and colleagues in Malawi showed that mastitis could be detected by elevated 
breast milk sodium concentrations. Mastitis occurred in 16 % of HIV-infected lactating women 6 
weeks postpartum. Elevated breast milk sodium concentrations, maternal plasma HIV-1 viral load 
and breast milk lactoferin were associated with increased risk of MTCT of HIV-1 by 6 weeks and 
12 months of age. They also found a correlation between breast milk HIV-1 viral load and plasma 
HIV-1 viral load. The median breast milk HIV-1 viral load was 700 copies/ml among women 
with HIV infected infants compared with less than 200 copies/ml among women with HIV 
negative infants at 6 weeks of age (P<0.001) (Semba et al., 1999). A study by John et al., 2000 
conducted in Kenya confirmed that breast abscess and mastitis are strongly associated with 
postnatal transmission. 
 
Replacement feeding with formula milk or exclusive breastfeeding has therefore been 
recommended. In many developing countries formula feeding is unaffordable and there is often a 
lack of clean water and proper hygiene resulting in greater risk of infection in the infant. The 
nutritional and immunological benefits of breastfeeding should be weighed against the risk of 
MTCT of HIV. Women who do not breastfeed may be identified as HIV infected and 
stigmatized by the community. In the ZEBS study by Kuhn and colleagues, the authors 
concluded that infants born to HIV-infected women who have high CD4 cell counts are at high 
risk if breastfeeding is stopped at any time before 16 months and that when maternal CD4 cell 
count exceeds 300cells/µL, there is a net benefit of continued breastfeeding for HIV-free 













There is insufficient data on the risk of HIV acquisition through different infant feeding practices 
and the associated risks and benefits (Rollins et al., 2004). Interventions are therefore needed 
urgently to reduce MTCT of HIV among breastfeeding populations in developing countries 
(Semba et., 1999; John et al., 2000, Kumwenda et al., 2008). 
 
 
1.6 Prevention of Mother-to-child transmission (PMTCT) of HIV   
 
1.6.1 Antiretrovirals (ARVs) for reducing the risk of mother-to-child 
transmission (MTCT) of HIV infection 
Antiretroviral (ARV) drugs, including nucleoside analogue reverse transcriptase inhibitors 
(NRTIs) such as zidovudine (ZDV) and lamivudine (3TC) and the non-nucleoside reverse 
inhibitor (NNRTI) nevirapine (NVP), either alone or in combinations have been shown in a 
number of studies, to be effective in reducing MTCT of HIV. These regimens reduce the risk of 
MTCT by decreasing viral replication and through prophylaxis of the foetus and infant during 
and after exposure to the virus (WHO, 2004). In high income countries, highly active 
antiretroviral therapy (HAART) has reduced the transmission rates to less than 1%, but HAART 
is not yet widely available in low and middle income countries.  
 
In 2003, WHO published guidelines for scaling up HAART in resource-limited countries for 
persons infected with HIV. By the end of 2007, 3 million people worldwide were estimated to be 
on HAART, yet less than a third of those needing HAART actually received it and there was a 
wide variation in coverage (WHO, 2008). Provision of HAART in resource poor settings has 












is grossly inadequate. Key challenges include a lack of human resources and skills, infrastructure 
and technology barriers, system deficits, and structured health care financing obstacles 
accompanied by a vertical programme mindset where programmes are run in isolation instead of 
having integrated services. Even in settings where resources are available, there is a tendency 
towards small-scale stand alone initiatives rather than  large scale system approaches, resulting in 
poor results, inconsistency in quality and high cost (Gazzard et al., 2006). 
 
On the demand side, the main challenge is the high burden of disease in most developing 
countries. The current technologies for monitoring critical parameters such as CD4 cell count 
and viral load are expensive and dependent on electricity and specialist operators. In most 
African countries, this has led to logistical problems associated with laboratory testing and long 
delays in the reporting of results (Gazzard et al., 2006). Ekong et al., 2004 in Nigeria, highlighted 
some of these challenges including the shortage of clinicians with adequate relevant skills on use 
of HAART. 
 
There are long-term challenges in the provision of HAART in sub-Saharan Africa, the region 
with the highest HIV prevalence in the world (UNAIDS/WHO, 2007). More than three in four 
(76%) AIDS deaths in 2007 occurred in sub-Saharan Africa, indicating the unmet need for 
antiretroviral therapy in the region. Various simpler and less costly ARV regimens have thus 
been offered to pregnant women and to their new born babies in developing countries because of 













1.6.2 PMTCT Programmes 
 
Programmes to prevent mother-to-child transmission (MTCT) of HIV have been successfully 
implemented in a number of developing countries. These programmes have had a major impact 
on paediatric HIV prevalence (WHO, 2006). The risk of MTCT can be reduced to less than 2% 
by interventions that include ARV prophylaxis given to women during pregnancy and labour, to 
the baby in the first few weeks of life and obstetrical interventions that include elective caesarean 
delivery (prior to onset of labour and rupture of membranes), (Dorenbaum et al., 2002, Read et 
al., 2005, Coovadia et al, .2007 and Kumwenda et al., 2008). In many resource-constrained 
settings, elective caesarean delivery is not feasible and it is often neither acceptable nor safe for 
mothers to formula feed. In such settings efforts to prevent HIV infection in infants are initially 
focused on reducing MTCT during labour and delivery. In order to increase the effectiveness of 
PMTCT programmes, many countries with high HIV prevalence have adopted simpler regimens 
that are less effective, beginning in the third trimester of pregnancy (Lallemant et al., 2004). 
 
ARV prophylaxis has thus become one of the most important interventions in the prevention of 
the transmission of HIV. A number of studies have been conducted to demonstrate the efficacy 
of various short-course regimens including SD-NVP alone (single dose for mother and infant) 
and SC-ZDV plus SD-NVP (maternal and infant) (Zaba et al., 2005). Available data from trials 
show that regimens using a combination of ARV drugs such as SC-ZDV plus SD-NVP (maternal 
and infant) were more efficacious than single drug regimens in reducing MTCT and that longer 
courses were more efficacious than shorter courses (Dabis F et al., 2003; Kumwenda et al., 
2008). If the goal of eliminating HIV infection in children is to be achieved, all women eligible 












countries must adopt more efficacious ARV regimens for preventing MTCT among pregnant 
women who do not yet require HAART (WHO, 2006). For a pregnant HIV-infected woman, 
such treatment reduces maternal mortality and morbidity and is an effective method of 
preventing MTCT of HIV since the well being of the mother would ideally improve survival 
chances of her baby. Treating a pregnant HIV woman should therefore be seen as a way of not 
only improving her health but also reducing the risk of MTCT especially for those women with 




























Table 2: Antiretroviral protocols for pregnant women and Infants 
 
Table 2: Guidelines for the implementation of the PMTCT programme adapted from policy and 
guidelines for the implementation of the PMTCT programme, South African National 
Department of Health, February 2008 
 
In 2009, the WHO produced new PMTCT guidelines. The WHO now recommends earlier 
initiation of ART for pregnant women, delivery of more patient friendly ARVs and prolonged 
use of ARVs to reduce the risk of MTCT. Once these new recommendations are implemented, 
HIV positive mothers or their infants will have to take ARVs during breastfeeding to prevent 
HIV transmission (WHO, 2009). WHO now recommends the initiation of ART at a CD4 cell 












patients co-infected with tuberculosis (TB). In the previous guidelines, HIV positive mothers 
were provided with ARVs only in the third trimester (beginning at 28 weeks). However, the new 
guidelines encourage HIV positive mothers to begin ARV treatment at 14 weeks of pregnancy 
and exclusively breastfeed their infants for the first twelve months of life. This will ensure a 
reduction in transmission and an increase in the infant’s chances of survival. These 
recommendations have the potential to reduce MTCT transmission to 5% or lower (WHO, 
2009). 
 
1.6.3 Review of evidence from PMTCT studies of ARV prophylaxis 
 
Randomised Controlled Trials (RCTs) to evaluate the efficacy of perinatal ARV prophylaxis 
regimens have been conducted since the early 1990s. The PACTG076 trial was the first to be 
conducted in the USA and France.  The trial evaluated the efficacy of antenatal and intrapartum 
SC-ZDV to the mother from 14 weeks and every 3 hours in labour and 6 weeks of postnatal SC-
ZDV to infants versus placebo. In this study all mothers gave their infants replacement feeding. 
Transmission was 7.6% in the SC-ZDV arm and 22.6% in the placebo group at 18 months.  
 
Following the publishing of the PACTG076 trial results, numerous RCTs providing ARVs to 
reduce MTCT were conducted in Africa and Thailand to make out less complex regimens that 
would be feasible in developing countries. Most of these studies made use of a placebo arm and 
this led to a debate among researchers on the use of placebos in these trials as the PACTG076 
study had shown that SC-ZDV decreases MTCT and that this should now be regarded as the 
standard of care. The first results released were from the Thai trial that assessed a short course 












compared to placebo. All infants were formula fed. This study revealed a transmission rate of 
9.4% at 6 months in the SC-ZDV group and 18.9% in the placebo group. The results of this trial 
led to the discontinuation of the placebo arm for other trials that were ongoing at that time 
including the PETRA study that was being conducted in South Africa, Uganda and Tanzania.  
 
The HIVNET012 trial in Uganda provided SD-NVP to mothers during labour and to infants 
within 72 hours of birth in the treatment arm and SC-ZDV was given during labour and for 7 
days thereafter to infants in the control arm in a breastfeeding population (Guay et al., 1999). 
This trial revealed a transmission rate of 11.8% in the treatment arm and 20.0% in the control 
arm at 6-8 weeks. This reduction was sustained at 18 months, with a rate of 15.7% compared to 
25.8% in the treatment and control arms respectively (Jackson et al., 2003). The World Health 
Organization thus recommended this cheaper and more feasible intervention in developing 
countries in 2004.  
 
The perinatal HIV prevention trial-2 (PHPT-2) equivalence trial in Thailand compared three 
treatment regimens in Thai women who were receiving SC-ZDV therapy at 28 weeks of 
pregnancy. In one group, mothers and their infants received SD-NVP (NVP-NVP regimen): in 
another, mothers and infants received SD-NVP and placebo (NVP-placebo regimen): and in the 
last group, mothers and infants received placebo (placebo-placebo regimen). The infants were 
also given 1 week ZDV therapy and were formula-fed. At the first interim analysis, the placebo-
placebo group was stopped. Among those women who delivered before the interim analysis, the 
as-randomized Kaplan-Meier estimates of the transmission rates were 1.1% (95% CI: 0, 3-2.2) in 












final per-protocol analysis transmission rate in the NVP-NVP group was, 1.9% (95% CI: 0.9-
3.0), was not significantly different from the rate in the NVP-placebo group (2.8%, 95% CI: 1.5-
4.1). The authors of this study concluded that, SD-NVP given to the mother with or without a 
dose of NVP to the infant, added to oral ZDV prophylaxis starting at 28 weeks’ gestation, is 
highly effective in reducing MTCT of HIV (Lallemant et al., 2004). 
 
A further study on the efficacy of SC-ZDV plus SD-NVP was conducted in a population in 
which 60% of the infants were breastfed in Cote d’lvoire (Dabis et al., 2003). Women in the 
DITRAME plus study received SC-ZDV from 36 weeks plus SD-NVP to the mother and infant 
at delivery (Dabis et al.,1999) and in a similar population, another study assessed the efficacy of 
SD-NVP added to SC-ZDV and 3TC (Dabis et al.,2003). 
 
These studies from Thailand and Cote d’lvoire indicated that SC-ZDV plus SD-NVP at delivery 
to the woman and infant was highly efficacious and suggested that SC-ZDV from 28 weeks 
gestation is more efficacious than SC-ZDV started at a later stage in pregnancy (WHO, 2004) 
 
Other trials were conducted to assess a variety of short course regimens (Wiktor et al., 1999, 
Dabis et al., 1999). The PETRA study assessed the efficacy of different regimens of SC-ZDV 
and 3TC, and the SAINT study compared a combination of SC-ZDV and 3TC (Moodley et al., 
2003). The studies are summarised in Table 3 which shows a comparison of Western Cape 
interventions with other trials conducted in other parts of the world from 1998 until 2007. HIV 
transmission rates for each of the studies are presented. The comments column indicates when 













The efficacy of different interventions was tested under ideal trial conditions and the 
effectiveness of PMTCT programmes in the field may not be the same (Alioum et al., 2001, 
2003). Barriers to the uptake of services are poor quality health services and inadequate 
community support for programmes to prevent MTCT. Some women may not attend ANC or 
may deliver at home and therefore may not receive adequate antepartum or intrapartum ARV 
prophylaxis (WHO, 2004). Many challenges remain with the implementation of effective 
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1.6.3.1 A review of the PMTCT programmes in the Western Cape Province in 
South Africa  
 
The Western Cape was the first province to initiate a PMTCT programme in South Africa. In 
January 1999, the Khayelitsha sub-district was selected as a pilot site to initiate a PMTCT 
programme in the province. The programme offered HIV counselling and testing, AZT from 34 
weeks gestation (300mg twice a day) and during labour as well as infant HIV testing. 
Replacement feeding was offered until 9 months to mothers who chose not to breastfeed. At 9 
months of age, children were tested and those who were positive were retested at 18 months. 
After delivery, women attended one of the eight local authority clinics every two weeks for 9 
months. Support groups played an important role in services offered both antenatally and 
postnatally (Abdulla et al., 2001). 
 
In 2001, the programme was extended to five more sites using NVP as a single-dose regimen for 
mothers and infants. The Khayelitsha sub-district continued to provide short course treatment 
with AZT. At the end of 2002, the South African Department of Health (DOH) implemented a 
pilot PMTCT programme nationally. Two pilot sites were purposively selected from each 
province (total of 18 sites) for the implementation of a PMTCT protocol developed by the DOH. 
The selected sites represented urban and rural sites. In addition, an evaluation of the pilot sites 
was conducted. The evaluation assessed the provision of VCT to pregnant women, appropriate 
counselling and support for safe infant feeding practices and follow up care to mother-infant 
pairs after delivery (McCoy et al., 2002). Doherty et al., 2005 found low coverage, with only 












consistent with other studies showing low uptake of PMTCT services in Africa (Dabis & Ekpini., 
2002).  Access to PMTCT was variable. 
 
The PMTCT programme in the Western Cape province was amended in July 2003 and mothers 
were given in addition to AZT from 34weeks, SD-NVP at the onset of labour and a weight 
adjusted single dose NVP to the infant within 72 hours after birth and 7 days of AZT, following 
the evidence from the study by Dabis F et al., 2003. Pregnant women were referred for HAART 
if eligible and PCR was provided for exposed infants.  The current policy and guidelines (2008) 
for the implementation of the PMTCT programme include dual antiretroviral prophylaxis 
consisting of SD-NVP plus SC-AZT initiated at 28 weeks of pregnancy for women with a CD4 
cell count greater than 200 cells / mm3 (WHO stage I-III) or CD4 cell count unknown and 
HAART for women with a CD4 cell count less than 200cells/mm3or with WHO stage IV 
disease. In instances where the mother has less than 4 weeks of AZT or a HAART regimen, the 
infant should be given SD-NVP and 28 days of AZT following the results of the study by 
Kumwenda et al., 2008 (Policy and guidelines for implementation of the PMTCT programme, 
National Department of Health, 2008). 
 
1.6.4 Methods for measuring effectiveness 
 
Researchers and policymakers often distinguish between the efficacy and the effectiveness of an 
intervention. Efficacy trials (explanatory trials) determine whether an intervention produces the 
expected result (effective) under ideal circumstances. Effectiveness trials (pragmatic trials) 
measure the degree of beneficial effect under ‘realistic situations’ i.e. clinical settings.  Hence, 












routine clinical practice and on outcomes essential for clinical decisions. The best method for 
evaluating efficacy and effectiveness is with randomized trials (Joubert & Ehrlich, 2007).  
 
Programme coverage or the proportion of HIV infected-exposed mother-infant pairs in a 
population that receives a PMTCT intervention (Stringer et al., 2003) is an important measure of 
effectiveness. However, a complex pathway, with a sequence of events needs to be covered 
before a mother-infant pair receives a PMTCT intervention. This pathway has been described as 
the PMTCT “cascade” (Figure 3)  and can be constructed from process indicators collected 
routinely by PMTCT programmes and health care facilities (Stringer et al., 2007). It is extremely 
important that every pregnant HIV-positive mother goes through all the steps of this cascade in 
order for the intervention to be effective. The sequence of steps that a mother has to follow are: 
1) she must seek antenatal care; 2) she must be offered HIV testing; 3) she must accept HIV 
testing; 4) she must receive her test result; 5) she must be offered prophylactic antiretroviral 
therapy; 6) she must accept prophylactic antiretroviral therapy; 7) services must supply and she 























         (1) 
Seek antenatal care 
 
 
         (2) 
Be offered HIV test 
                           
            (3) 
 Accept HIV test 
 
                                                        
     (4) 
Get HIV test 
 
                                                             
         (5) 
Agree to ARV 
                                                                                                                                
 
                                                                             
           (6) 
Adhere to ARV 
prophylaxis
        (7)  Adhere to infant 
ARV doses  
Figure 3: PMTCT -“cascade”. Steps 1, 2, 3 and 4 would apply to any women presenting in an 
antenatal institution while steps 5, 6 and 7 apply only to HIV-positive women. 
 
 
1.7 Challenges of measuring effectiveness of PMTCT programmes 
 
In most countries PMTCT programmes fail because pregnant HIV positive women miss one or 
more of the events outlined in figure 3. One in four HIV-infected pregnant women in Lusaka, 
Zambia did not adhere to SD-NVP that had been distributed antenatally for self administration at 












to 60% of HIV-infected women declined SC-ZDV prophylaxis (Meda et al., 2002; Songok et al., 
2003). Reasons for women rejecting prophylaxis included lack of education, not understanding 
the purpose of ARV prophylaxis, denial and fear of stigma from members of the community 
(Painter et al., 2004). 
 
Effectiveness of PMTCT programmes has been measured in several ways in different countries. 
In Zambia, Stringer et al., 2005, estimated the effectiveness of a city-wide PMTCT programme 
using anonymous cord blood surveillance to determine HIV serology and NVP levels. In this 
study, 10 public sector delivery centres in Lusaka participated with a total of 10 194 women 
delivering over a three month period. The study identified three crucial areas of programme 
effectiveness that were not measured by PMTCT-cascade indicators (Stringer et al., 2007). 
Women who did not accept an HIV test were more likely to be infected compared to those who 
accepted it. Secondly, some women were misclassified as negative when in fact the laboratory 
result at the time of delivery confirmed they were positive and therefore did not receive ARV 
prophylaxis. The proportion of women who were infected during pregnancy was not known and 
this may account for some of the discrepant results.  Finally, one third of women who were given 
NVP for self administration did not swallow the tablet. Thus, even in a well implemented 
PMTCT programme, effectiveness may be diminished. 
 
One of the ways of evaluating the effectiveness of PMTCT programmes is to have exposed 
infants born to HIV-infected women tested at 6 weeks using polymerase chain reaction (PCR) 
tests.  Antibody testing using the ELISA technique is inaccurate as maternal antibodies may 












infants is only informative before the age of 18 months if the test result is negative. With 
virologic assays including HIV-1 DNA or RNA assays, the diagnosis can be established within 
several weeks of birth among non-breastfed infants (Read, 2007). This can only be used to assess 
intrapartum and peripartum transmission effectiveness of programmes (Reithinger et al., 2007) 
and later testing is required to assess transmission through breast feeding. In many developing 
countries PCR is not available. 
 
1.8 Rationale and Justification 
 
Intrapartum and perinatal transmission of HIV account for a large part of paediatric HIV 
incidence in developing countries.  In clinical trial settings studies showed that simple, short-
course ARV regimens and HAART are effective in reducing vertical transmission of HIV 
(Lallemant et al., 2000).  
 
PMTCT coverage appears low in many developing countries and the population effectiveness of 
the PMTCT programmes has not been estimated. It was thus decided to estimate the coverage of 
PMTCT and compare this to data that is collected on the PMTCT cascade.  
 
1.9 Aim and Objectives 
 
This study aimed to estimate the effectiveness of the PMTCT programme by determining SD-
NVP coverage at delivery in HIV-infected pregnant women and their infants from Mitchell’s 

















1.9.1.1 Primary objective 
 
The primary objective was to measure PMTCT coverage in pregnant women and their infants 
delivering at Gugulethu and Mitchell’s Plain public sector Midwife-run obstetric units (MOUs) 
and in women referred from these units to Mowbray Maternity Hospital in the Western Cape 
region in South Africa. 
 
 1.9.1.2 Secondary objectives 
The secondary objectives were: 
• To determine the prevalence of HIV in pregnant women at delivery in the two 
communities 
• To determine NVP coverage in the study population 
• To determine maternal adherence to NVP 
• To construct the PMTCT cascade in order to estimate missed opportunities for the 
prevention of vertical transmission of HIV and to determine predictors of coverage to 

















                                                         CHAPTER 2:  
2.1 METHODS 
2.1.1 Study design 
 
This was a cross-sectional study. It was part of a larger study conducted in six communities in 
four countries (South Africa, Zambia, Coted’Ivoire and Cameroon). This study was conducted 
between November 2007 and May 2008 and only included public sector delivery units in 
Mitchell’s Plain and Gugulethu in the Western Cape province of South Africa. 
 
2.1.2 Population and Sampling 
 
The population was all pregnant women delivering at Mitchell’s Plain and Gugulethu Midwife-
run Obstetric Units (MOU) and those who were referred from these Units to Mowbray Maternity 
Hospital.  
 
The study sample was all women delivering at these MOUs between 12 November 2007 and 30 
May 2008. Presuming SD-NVP coverage of 60% in the population, we required a sample size of 
365 HIV positive women to detect this proportion with 95% confidence and a 5% margin of 
















 2.1.3 Measurement 
 2.1.3.1 Outcome measures 
 
Coverage was defined as the proportion of infected mother and exposed-infant pairs that 
received both the maternal and infant SD-NVP. Infant HIV-exposure was ascertained by cord 
blood antibody testing. Maternal SD-NVP dosing was determined by cord blood chromatography 
and infant SD-NVP dosing from the clinical records. It has been shown that maternal dosing on 
its own may fail to achieve a long-lasting infant prophylactic level, especially if the mother 
ingests the SD-NVP an hour or less before delivery and hence infant prophylaxis was measured 
as well (Mirochnick et al, 2003 ). Infant dosing on its own has been shown to have modest 
prophylactic efficacy (Taha et al, 2003). Maternal and infant SD-NVP coverage as the primary 




A surveillance form was used to collect demographic and PMTCT related data from the clinical 
records. After every delivery cord blood was anonymously collected from the discarded placenta 
of all live-born deliveries. Approximately 5cm3 of cord blood were obtained in an anticoagulated 
EDTA tube fixed with a unique number. In the event of a failed attempt to obtain specimens the 
reason was noted. In the case of twins, two cord blood specimens were obtained from each 
placenta. Specimens were sent to the laboratory together with surveillance forms with 
information collected from the patient’s folder. Information collected included the health facility 
where the woman received antenatal care and where she delivered, whether she accepted testing, 












mother and infant, whether it was a normal delivery or caesarean section, and the baby’s birth 
weight (data collection forms attached in Appendix B). Cord blood specimens were then 
analysed at the laboratory for HIV antibodies via an Abbott Determine® HIV-1/2 Test. Every 
tenth specimen was retested by a second observer for quality purposes. Dried blood spot (DBS) 
specimens were tested for SD-NVP presence via chromatography if the cord blood tested 
positive for HIV. 
 




Detection of SD-NVP in dried blood spots (DBS) was carried out by a validated method using 
minor modifications of the method of Koal et al., 2005.   SD-NVP was extracted from the DBS 
with 80% methanol, 20% 0.2M zinc sulphate containing neostigmine as internal standard.  HPLC 
was carried out on a Phenomonex Fusion RP column (5x2x4um) using a methanol/10 mM 
ammonium acetate gradient to effect elution.  Detection was achieved using an Applied 
Biosystems API 3200 tandem mass spectrometer in the MRM detection mode. 
 
For qualitative assessment, blank and quality control cut-off samples were included with each 
run. The limit of detection for SD-NVP drug was set at 0.1 ug/ml.  Values detected above this 
limit were reflected as positive and those below as negative. For quantitative assessment, 
standard curves were run in the range 0.1 – 10 ug/ml and appropriate quality control samples run 
with each batch.  The limit of quantification was 0.1 ug/ml.  Inter and intraday coefficients of 














                                                            CHAPTER 3 
3.1 ETHICS AND DISSEMINATION  
3.1.1 Ethical Review 
 
This protocol was reviewed and approved by the University of Cape Town Ethics committee 
REC REF: 038/2007. The Ethics approval letter is attached in Appendix A.  
3.1.1.1 Informed consent 
 
Since blood was collected anonymously informed consent was not obtained. All women 
attending antenatal clinics at these delivery units were informed of the study.  
 
Informed consent was not obtained for the following reasons: 
1. There were no risks to the patient as blood was taken from discarded placentas 
2. The rights of the patients were not violated and access to health care was not affected 
since all patients in the study facilities had access to PMTCT and HIV services during 
antenatal care and delivery. The HIV tests were conducted anonymously and there was 
no link to the names of patients. In this way, confidentiality was assured.  
3. If consent was asked, certain women might not have agreed and this may have led to 
systematic bias. In a study conducted in Lusaka, Zambia, it was shown that women who 
















The collection of cord blood specimens was conducted in an unlinked, anonymous manner to 
protect the confidentiality of patients. Specimens were coded according to the facility from 
which they were collected.  
3.1.1.3 Benefits 
 
There was no direct benefit to participants in the study. However, findings from this study may 
assist with improving PMTCT programmes in these areas.  
3.1.1.4 Confidentiality 
 
Blood was collected anonymously and no data was linked to patient identities. All surveillance 
data were stored securely. Study collection forms and laboratory specimens were identified by a 
coded number. Specimens were stored for the period of the study to test for HIV seropositivity 
and NVP levels. All data bases were secured with password-protected access systems. 
 
                      





















                                    CHAPTER 4:  
4.1 DATA MANAGEMENT AND ANALYSIS 
 
Data from all questionnaires were coded and double entered into an MS Access database and 
exported to STATA, version 10 software for cleaning and analysis. Data was transformed into a 
format suitable for logistic regression analysis. String variables were converted into numeric 
variables and vice versa.  
 
Data were analysed using STATA. The first step was to check for multi-colinearity effect 
between variables. Statistical tests (correlation test and chi-square test) and clinical knowledge 
were used to identify variables with multi-colinearity effect. Some of the variables that were 
found to be collinear were; whether the mother was precounseled or not and whether they 
accepted the HIV test. HIV result and NVP result were also collinear and finally HIV result and 
maternal NVP ingested. Whether or not a mother was on HAART was correlated with mode of 
delivery and test acceptance. Therefore, these variables cannot be both included in the same 
model as using them together would create a multi-colinearity effect. These variables are 
collinear because the later variable is a direct consequence of the former. 
 
Univariate data were analysed according to the MOU attended. In the first step, exploratory data 
analysis was carried out to compute distributions and summary statistics of individual variables. 
Bivariate data analysis was the next step to identify any correlation between variables to identify 
significant influential variables of SD-NVP coverage. Variables found statistically significant at 
significance level 0.05 or strong evidence in the literature of their significant importance were 













In the second step, binary logistic regression was used to identify and measure the influence of 
the predictor variables identified from the first step. Two approaches were used to carry out 
logistic regression in order to arrive to a model that best describes SD-NVP coverage. The first 
approach entailed building the model by starting off with an empty model, which is a model 
containing only the independent variable, then all dependent/explanatory variables were added to 
the model, in a stepwise fashion, in order of significance (statistically/biologically). A p-value of 
< 0.05 (less than 5% chance of random error) was used as a cut-off point for significance level to 
identify independent factors. In all model development processes, the log likelihood ratio and 
Alkaiki’s information criterion AIC were used to select the best-fit model. 
 
The second approach used was the backward elimination variable selection where, all variables 
were initially brought into the model equation. The coefficient of the least significant variable 
was then tested for significance at probability 0.1 (pre specified level of significance), that is 
giving a 10% chance of random error. When the least significant variable was found to be 
significant, then all variables were included in the model and the process stopped. If it was not 
significant, the variable was excluded; the model refitted without this variable and the process 
was repeated. The process stopped when all regression coefficients were significant at a 10% 
level of significance. The two approaches used identified the same predictor variables, but only 















4.1.3 Statistical methods 
 
All data was analysed using STATA, version 10 software developed by StataCorp LP, USA 
(Copyright 1985-2001). To assess comparisons of age, gravidity, birth weight of infants and 
other continuous variables between groups, unpaired two-tailed Student t-tests, ANOVA for the 
comparison of mean differences and 95% confidence intervals around the mean difference were 
used. Categorical variables were analysed by chi-squares, and 95% confidence intervals for the 
odds ratios were computed. Proportions on the HIV prevalence and ARV coverage were 
































                                                      CHAPTER 5:  
 
5 RESULTS 
5.1 Baseline characteristics 
 
5.1.1 Specimen collection rate 
 
At the Mitchell’s Plain, Gugulethu MOUs and at the referral hospital at Mowbray, 2278 women 
gave birth to live infants between November 2007 and May 2008. From these deliveries, we 
obtained 2198 specimens and thus the collection rate was 96.5% (Fig 4.2) and 64.8% (1425) of 
these were from Mitchell’s Plain while the rest were from Gugulethu (Fig 4.1). Women from 
whom we were unable to obtain cord blood specimens did not differ from those from whom the 
cord blood was obtained with regards to age, gravidity, or whether they had been offered HIV 
testing in antenatal care (reasons for cord blood not collected are illustrated in Fig 4.4). The 





















Table 4.1: Demographic characteristics of women from Mitchell’s Plain and Gugulethu MOUs  
Facility                                                   Baseline characteristics 
                                                                        Age       Gravidity                 
                                                   Mean            25.0          2.0  
Mitchell’s plain                        Range            13-45                     1-13            
 (N=1472)                                  SD                  5.7                         1.2 
                                                   Mean              25.6                       2.1 
Gugulethu                                 Range            12-47                      1-7 
(N=803)                                     SD                   5.9                          1.1 
*P-value                  0.0304        0.1760 
*p-value tests for the equality of means for the specific characteristics in the two samples 
 
The 2198 women from whom blood was collected had a mean age of 25.2 years (range, 12-47 
years) and standard deviation 5.8. Their mean gravidity (including the current pregnancy) was 
2.0 (range, 1-13) (Table 4.1). Most of the women (94.6%) had a normal (vaginal) delivery and 
5.4% had a caesarean delivery for both facilities combined. On analyzing mode of delivery by 












caesarean delivery were observed. Less than 10% of women had had an HIV test before the 
current pregnancy. Amongst those women who had previously tested, only 39 (1.8%) had tested 























Cord blood HIV positive 
(19.7 %) 
Figure 4.2: Collection rate and HIV prevalence amongst women who had a specimen collected. 
 
Of the 2198 (96.5%) specimens collected, 1851 (84.2%) were tested for HIV (Fig.4.2) and 365 
(19.7%) tested HIV positive. Of the women who tested positive on the cord blood, 20.6% had 
tested negative at their first antenatal clinic visit. A detailed description of the demographic 













Table 4.2: Key characteristics of the women who delivered at Mitchells Plain and Gugulethu 
during the study 
                                               Sites 
Characteristics Mitchell’s Plain Gugulethu Total 
Number of women attending  1249 (89.0%) 660 (87.4%) 1909 (88.5%)      
first ANC visit at the clinic at 
which they delivered 
269 (18.9%) 185 (23.9%) 452 (20.7%) Number of women with <=2 
ANC visits 
Number of women with >2 1156 (81.1%) 588 (76.1%) 1744 (79.3%) 
ANC visits 
caesarean 58 (4.1%) 60 (7.8%) 118 (5.4%) Mode of 
delivery normal (vaginal) 1362 (95.9%) 708 (92.2%) 2070 (94.6%) 
120/1425 (8.4%) 69/773 (8.9%) 189/2198 (8.6%)        Number of women who had an 
HIV test before this pregnancy 
Number pre-counselled 1254/1425 (88%) 622/773 (80.5%) 1876/2198 (85.4%)        
1254/1425 (88%) 596/773 (77.1%) 1851/2198 (84.2%)        Number of women tested for  
HIV during the study 
11.8 (149/1255) 34.5(216/596) 19.3 (365/1851) % HIV prevalence 
90 (60.4%) 139 (64.4%) 229 (62.7%) Number of HIV-infected 
women who received NVP 
Number of infants recorded as 128/149 (85.9%) 183/216 (84.7%) 311/365 (85.2%) 
receiving NVP 
Number of women positive for 106/149 (71.1%) 161/216 (74.5%) 267/365 (73.2%) 
AZT as above 
12/149 (8.1%) 11/216 (5.1%)  23/365 (6.3%) Number of women positive for 
HAART as above 
86/149 (57.7%) 125/216 (57.8%) 211/365 (57.8%) Number of HIV infected 
women with evidence of  NVP 
in cord blood 













Table 4.2 illustrates key characteristics of the two sites of the 2,198 women who delivered at 
these facilities during the study, 1,909 (86.9%) had gone for their first ANC visit at that facility. 












Of the 1851 specimens collected 365 (19.7%) tested HIV positive and 229 (62.7%) of mothers 
received SD-NVP according to the clinical records but only 57.8% had evidence of NVP in the 
cord blood quantified by HPLC. According to the clinical records 85.2% of infants born to HIV-
infected mothers were given ARV prophylaxis (Figure 4.4). Coverage, defined as the proportion 
of infected-exposed mother-infant pairs that received both the maternal and infant NVP doses 
was 202/365 (55.3%, Fig 4.3). There was no significant difference in SD-NVP uptake by infants 
between the two facilities. The cascade was similar for the two sites. These statistics are 
summarised in figure A2 in Appendix A.  
 
Figure 4.3: SD-NVP  coverage for pregnant women delivering in Mitchell’s Plain and 






































1876 (85.4%) Women pre-test counselled  
     1851 (84.2%) women tested 
161 had tested previously (repeated testing) 
365 (19.7%) Women HIV+ 
229 (62.7%) HIV+ women who received NVP 
311/365 (85.2%) babies born from infected 
mothers received NVP 
304 (13.9%) missing 
results 
25 missing results 
136/365 women negative for NVP  
6.3% also received HAART 
73.2% also received AZT 
61.6% received NVP + AZT 
1527(69.5%) HIV- women 
2198 (96.5%) cord blood specimens collected  
2278 women gave birth to infants in the 
maternity obstetric units Reasons for specimen not collected 
Clotted specimens 
Forgot to collect specimen 
Unspecified reasons 
262 (71.8%) babies born from infected 
mothers received replacement feeding 
202/365 (55.3%) mother infant pairs who 
received NVP 
211/365 (57.8%) HIV+ women with evidence of NVP 
in cord blood 
Figure 4.4 Surveillance study profile. Missing data for variables; mother’s age 6 (0.36%), gravidity 12 (0.55%), 












Table 4.3: Variables identified from the chi-square test to be important predictors of NVP coverage 
Variable                                                        Chi2 (1)                                       Chi2 p-value 
Mode of delivery                                                9.6235                                                0.002 
Maternal NVP                                                   29.6825                                             <0.001 
Mother accepted HIV test                               86.1417                                              <0.001 
Gravidity                                                          9.9872                                                   0.041 
st ANC visit in current facility     57.9133                                                <0.001 Attended 1
Maternal HAART                                           11.3166                                                  0.003 
 
Factors that were identified from the chi-square as important predictors of NVP coverage are 
presented in table 4.3 with the corresponding Chi-square and p-values.  
 
5.1.2 Predictors of NVP coverage 
 
Factors associated with NVP coverage (selected from the logistic regression model) are 
presented in table 4.4.  
 
Table 4.4: Factors associated with NVP coverage 
Variable                                              Crude   OR               Adjusted OR             P-value    
ANC visits                                          1.23(0.67-2.23)          2.02 (1.04-3.91)         0.04                               
First ANC visit in current facility      5.62 (3.14-25.67)        4.82 (1.29-18.01)       0.02                             
Normal vaginal delivery                    0.31 (0.10-0.91)           0.39 (0.12-1.30)         0.13                           
Gravidity = 2                                      0.83 (0.63-1.08)          0.56 (0.32-0.98)          0.04                              
 
Factors associated with NVP coverage included, firstly, the number of ANC visits, secondly, 












who had 2 or more ANC visits prior to delivery were more likely to adhere to SD-NVP 
compared to those who made less than two visits, OR 2.02 (P= 0.04). Having the first ANC visit 
in the current facility was associated with improved SD-NVP coverage, OR 4.82 (P= 0.02). 
Women who had at least two pregnancies in their lifetime were more likely to adhere to 




















































                                             CHAPTER 6:  
 
 6 DISCUSSION 
 
This study was conducted about five years after the implementation of the PMTCT programme 
throughout the Western Cape in 2001 and nationally since 2002.  The programme in the Western 
Cape was based on the HIVNET 012 NVP regimen and the provision of replacement feeding to 
all infants whose mothers chose to formula-feed. In 2002-2003 dual therapy (SD-NVP plus 
AZT) was introduced. However, the impact of the PMTCT programme in South Africa has not 
been significant (Jackson et al., 2007). Although the HIV testing rate had reached 69% in 
2006/2007 (Barron et al., 2007), a third of HIV positive women did not obtain NVP regardless of 
the national antenatal coverage rate of above 90% and 84% of births attended to by trained health 
professionals (Day & Gray, 2006).  
 
This study assessed HIV prevalence and NVP coverage at two Midwife-run Obstetric Units in 
the Western Cape. The prevalence of HIV in Gugulethu (34.5%) and in Mitchell’s Plain (11.8%) 
was similar to the 2008 antenatal surveys conducted in these MOUs at the time of the study. 
Findings from this study demonstrate that despite a seemingly robust PMTCT programme in the 
Western Cape Province, not all HIV-exposed infants are getting the appropriate prophylaxis and 













Compared to other provinces in South Africa the Western Cape has a well functioning PMTCT 
programme and yet in the current study, only 62.7% of HIV-infected women received at least 
SD-NVP, according to the clinic records. There was a large proportion (37.3%, Fig.4.4) of HIV 
infected women whose blood did not have NVP present according to cord blood 
chromatography. This could mean that, either, the infected women did not actually ingest the 
SD-NVP given to them in ANC or they were not tested and never received SD-NVP. The 
observed low NVP coverage (55.3%, Fig.4.3) calculated as the proportion of infected mother and 
exposed-infant pairs that received both the maternal and infant SD-NVP, could perhaps be 
attributed to the short duration between ingestion of SD-NVP and delivery and hence the absence 
of NVP in the cord blood specimens. Unfortunately no information was collected on the interval 
between maternal dosing and delivery.  
 
Evidence from previous studies showed that there was an association between time of maternal 
dosing and NVP plasma concentrations. Stringer et al., 2003, illustrated that women who 
delivered less than an hour after NVP ingestion had a lower mean NVP cord blood concentration 
compared to those who delivered at least two hours after they ingested NVP (p<0.001). Lower 
NVP concentrations were associated with lower cord blood concentrations and a shorter interval 
between maternal dosing and delivery (i.e. women delivering less than 1 hour after ingesting 
NVP).   
 
Jackson et al., 2006 also assessed the association of length of time between ingestion of SD-NVP 
and delivery and concentration of NVP in cord blood. The median NVP cord blood 












women who reported taking NVP more and less than 1 hour before delivery respectively 
(P<0.001). The results demonstrated that cord blood NVP concentrations correlated well with 
report of NVP administration and timing of dose before delivery.   
 
The fact that 20.6% of women tested negative at their first antenatal clinic visit and yet tested 
positive on cord blood indicates that seroconversions may have occurred later in pregnancy or an 
incorrect HIV test result was recorded in the folder and this may contribute to the PMTCT 
programme failure. There may also have been false negative cord blood results. Similar findings 
were reported by Stringer et al., 2005 who found that 13 of the 134 ‘seroconverters’ (9.7%) were 
also NVP positive and hence concluded that, around 10% of the apparent seroconversions can be 
attributed to errors in the surveillance exercise. Stringer et al., 2005 emphasized that, whether 
false- negatives in ANC derive from laboratory errors, clerical errors at the level of the antenatal 
clinic, or from actual recent infection, the result is the same-failed coverage (Stringer et al. 
2005). 
 
More efficacious PMTCT regimens such as triple therapy and HAART have been advocated to 
prevent PMTCT in developing countries. Although not as efficacious, the provision of single 
dose NVP is the simplest and most feasible intervention available. The low NVP coverage in this 
study indicated that it may be more important to improve coverage before extending programmes 













Failures occurred at each stage of the PMTCT cascade (Fig.4.3 and Fig A2). Interventions are 
required at each stage of the PMTCT cascade in order to improve programme coverage, and 
consequently programme effectiveness.  
 
Three important predictors of NVP coverage were identified in this study. Having more than two 
ANC visits increased the number of opportunities for women to enter the PMTCT programme as 
health workers would have had more time to reinforce the importance of being part of the 
PMTCT programme and had another opportunity to counsel and test them. Women with at least 
two previous pregnancies were more experienced and more sensitized to PMTCT and the 
importance of testing during pregnancy. Thirdly women who had their first ANC visit at the 
facility where they delivered were easier to follow up and there was greater continuity of care. 
These women were also likely to be less mobile and of higher socio-economic standing. 
 
The current study findings are consistent with findings from previous studies. A number of 
factors have been implicated in low maternal adherence to SD-NVP prophylaxis and 
consequently low coverage. In Rwanda, Delvaux et al., 2009, found that women who had less 
than two ANC visits, who were unmarried, less educated and those offered testing after their first 
antenatal clinic visit were more likely to be non-adherent to SD-NVP prophylaxis. In other 
studies women who were less than 20 years of age, single, having their first pregnancy, and who 
were less educated and of low socio economic status were less likely to undergo HIV testing and 
hence would not receive PMTCT prophylaxis if HIV-infected (Thierman et al., 2006). Similar 













Another critical thing would be to emphasize recognition of labour onset (i.e. it is crucial to take 
SD-NVP at the correct time, and hence, it is better to give mothers NVP beforehand so that they 
can take it when they start labour at home rather than only when they get to the MOU, to allow 
the drug to reach its peak concentrations before delivery) to mothers enrolled in PMTCT 
programmes and this could be done during counselling sessions.  
 
There are limitations to this study. This was a cross-sectional study and a longitudinal study 
would have been a better study design since it would have been possible to follow study 
participants and obtain transmission rates. It was not possible to conduct a longitudinal study for 
ethical reasons as all women who were identified as HIV-infected would have had to be referred 
for the best care available, and thus it would not have been possible to observe the cascade. 
Another limitation of this study was that the timing of the maternal dose was not documented 
and this limited the ability to correlate maternal adherence with duration since ingested. 
Demographic information such as marital status, socio-economic status and level of education 
was not collected and this could possibly have provided more information on variables 
associated with failed coverage in the PMTCT cascade. Cord bloods were anonymously 
collected and only information from the clinical chart was collected.  
 
HAART is recommended as standard of care for women with CD4 cell counts less than 
200cells/µL in the Western Cape. No information on CD4 cell counts of HIV-infected women 
was available and thus it was not possible to assess the proportion of women who should have 












from HST shows that about 87.2% of pregnant women in the Western Cape deliver in health 





                                                      CHAPTER 7: 
7 CONCLUSION 
 
In conclusion, only 62.7% of HIV-infected women in the Western Cape received at least SD-
NVP. For PMTCT services to be successful, each mother-infant pair should go through a cascade 
of events. Coverage was low in this study and different interventions need to be introduced at 
each stage of the cascade in order to improve PMTCT coverage.  
 
Policy makers should first focus on ensuring that HIV testing rates increase. The findings from 
this study demonstrate that increasing the effectiveness of a PMTCT programme depends on a 
number of factors and resources should be better spent in maximizing coverage of simple and 
moderately effective interventions such as SD-NVP, and later use more efficacious drug 
regimens when programme effectiveness has been established. Key to improving PMTCT 
programme are, increasing the uptake of the programme, using more efficacious regimens 
compared to SD-NVP, and ensuring that women with CD4 cell counts < 200 cells/µL are placed 
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ingesting NVP with NVP 
present 
Mitchell’s 1472 1425(96.8%)   149/1255 
(11.8%) 
408 (65.1%) 90/149 (60.4%) 86/149 
(57.7%) Plain 






125/216    
(57.8 %) 
 
The ARV coverage rates were calculated from the proportion of HIV positive women in the 
sample who had NVP detected in the cord blood. Figure A1 (a) and A1 (b) depict the rates in 














      Figure A1 (a) Uptake of ARV prophylaxis for HIV-positive pregnant women  
 
 
Figure A1 (b) Percentage uptake of ARV prophylaxis for HIV-positive pregnant women in 
the surveillance population. .*NVP result positive indicates the number or percentage of 














Figure A1 (a) and A1 (b) demonstrate uptake of NVP by pregnant women in crude numbers and 
percentages respectively. The two figures represent all the women in the surveillance population 
stratified by facility. 
 
Cord blood specimen collection was very high, with 96.8% and 95.9% specimens collected at 
Mitchell’s plain and Gugulethu MOUs respectively. The prevalence of HIV in Gugulethu was 
34.5% while in Mitchell’s plain it was 11.8%. The HST barometer results for the city of Cape 
Town indicate that the HIV prevalence among ANC clients for 2006/7 was 16, 8% while the 
HIV survey showed a prevalence of 17% (CI: 15.5%-18.4%).The Mitchell’s plain prevalence 











Figure A2 Attrition cascade among women in the surveillance population. This figure demonstrates the sequence of events that 
women in the surveillance population went through in-order to attain prevention of MTCT of HIV service coverage. Step A represents 
all women delivering in each of the two facilities in the surveillance population. In Mitchell’s plain, 60.4% (90/149) women were  
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